Chemotherapy and radiation therapy remain standard for locally advanced and metastatic cervical cancer. However, they often ...

Photo: Esteworld Opens Its First Representative Office in the UK in London ...

(2) Legal settlements, net of insurance proceeds, represents the net impact of legal settlements reached in the period. For the six months ended June 30, 2025, amount primarily includes the net impact ...

Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its ...

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

Gross profit was $14.1 million in the second quarter of 2025, or 69.8% of revenue, compared to $11.1 million, or 68.8% of revenue, in the same period in 2024. The increase in gross margin was ...

During the fireside chat, Drs. Campagna and Nikodem will highlight recent corporate updates, progress on lanifibranor and the Phase III NATiV3 trial in MASH and discuss the Company’s broader R&D ...

Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole : IVA - ISIN : FR0013233012) et sur le marché Nasdaq Global Market aux Etats-Unis (symbole : IVA).

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN ), reiterates investor confidence and estimated asset value over $10 billion.

DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BHIANT, the workforce development arm of BioNTX, is charting new ground in biotechnology talent development and industry collaboration, strengthening North ...

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed ...

Basel, Switzerland – August 11, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient in a ...